CAS 149092-50-2|AG-825
| Common Name | AG-825 | ||
|---|---|---|---|
| CAS Number | 149092-50-2 | Molecular Weight | 397.471 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 689.3±65.0 °C at 760 mmHg |
| Molecular Formula | C19H15N3O3S2 | Melting Point | / |
| MSDS | USA | Flash Point | 370.7±34.3 °C |
Names
| Name | ag 825 |
|---|---|
| Synonym | More Synonyms |
AG-825 BiologicalActivity
| Description | AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive ErbB2 inhibitor which suppresses tyrosine phosphorylation, with an IC50 of 0.35 μM. AG-825 displays anti-cancer activity[1][2][3]. AG825 significantly accelerates apoptosis of human neutrophils[4]. AG-825 is a potential agent for overcoming Mn-induced neurotoxicity or AD development[5]. |
|---|---|
| Related Catalog | Signaling Pathways >>Apoptosis >>ApoptosisResearch Areas >>CancerSignaling Pathways >>JAK/STAT Signaling >>EGFRSignaling Pathways >>Protein Tyrosine Kinase/RTK >>EGFR |
| Target | ErbB2:0.35 μM (IC50) EGFR:19 μM (IC50) |
| References | [1]. Wolfson E, et al. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer. Cell Death Dis. 2018 Jan 19;9(2):47. [2]. Gazit A, et al. Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36(23):3556-64. [3]. He H, et al. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 2001 May-Jun;7(3):191-202. [4]. Rahman A, et al. Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation. Elife. 2019 Oct 15;8. pii: e50990. [5]. Ling J, et al. Identifying key genes, pathways and screening therapeutic agents for manganese-induced Alzheimer disease using bioinformatics analysis. Medicine (Baltimore). 2018 Jun;97(22):e10775. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 689.3±65.0 °C at 760 mmHg |
| Molecular Formula | C19H15N3O3S2 |
| Molecular Weight | 397.471 |
| Flash Point | 370.7±34.3 °C |
| Exact Mass | 397.055481 |
| PSA | 162.77000 |
| LogP | 2.89 |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.733 |
| InChIKey | KXDONFLNGBQLTN-WUXMJOGZSA-N |
| SMILES | COc1cc(C=C(C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O |
| Storage condition | −20°C |
| Water Solubility | DMSO: soluble |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | 22-24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles2
More Articles| Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma. Int. J. Cancer 125(12) , 2783-91, (2009) The sodium iodide symporter (NIS) mediates iodide uptake into the thyroid. Because of this mechanism, differentiated thyroid cancer is susceptible for radioiodine therapy. Functional NIS expression in... | |
| Degradation of HER2 receptor through hypericin-mediated photodynamic therapy. Photochem. Photobiol. 86 , 200-5, (2010) Current treatment of breast cancer is often affected by resistance to therapeutics, for which the human epidermal growth factor receptor 2 (HER2) may be responsible. Here, we report for the first time... |
Synonyms
| 2-Propenamide, 3-[3-[(2-benzothiazolylthio)methyl]-4-hydroxy-5-methoxyphenyl]-2-cyano-, (2E)- |
| (2E)-3-{3-[(1,3-Benzothiazol-2-ylsulfanyl)methyl]-4-hydroxy-5-methoxyphenyl}-2-cyanoacrylamide |
| TYRPHOSTIN C15 |
| (2E)-3-{3-[(1,3-benzothiazol-2-ylsulfanyl)methyl]-4-hydroxy-5-methoxyphenyl}-2-cyanoprop-2-enamide |
| 5-[(Benzothiazol-2-yl)thiomethyl]-4-hydroxy-3-methoxybenzylidenecyanoacetamide Tyrphostin C15 |
